News | December 24, 2024
Syensqo and Emulseo collaborate to advance microfluidic technology in healthcare sector
Exploring new opportunities within the fast-growing market of microfluidics
Exploring new opportunities within the fast-growing market of microfluidics
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
GFP is a common fusion protein tag that enables protein expression to be monitored, quantified, and localized within the complex environment of the cell
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
The company has received five final approvals
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
Subscribe To Our Newsletter & Stay Updated
